Celgene Corporation (NASDAQ: CELG) is supposed to be one of the more promising biotechs out there. After all it was worth some $29.6 billion in market capitalization at Wednesday’s close. Now shares are down more than 12% and destroying more than $3 billion in market value.
The biotech giant announced that it has now withdrawn its new indication submission for Revlimid to European regulators. Revlimid is ultimately seeking approval for the cancer multiple myeloma which affects certain white blood cells. While today’s implosion is a bad one, Celgene was quick to not that it plans to resubmit its Revlimid application with more current data.
Celgene also said that it is re-evaluating Revlimid’s newly diagnosed submission to the U.S. Food and Drug Administration. It is now targeting a new drug application with the FDA at some point in 2013. The company said that it will continue with applications for Revlimid in Switzerland, Australia and other markets.
Thomson Reuters had estimates of $4.79 EPS and $5.47 billion in sales in 2012 and the consensus was $5.61 EPS and $6.17 billion in revenues in 2013. Analysts will likely be taking those figures down for sales and for higher R&D expenses. The consensus price target before this news came out was almost $85.00.
Celgene shares had already been having problems as the $67.16 close compared to a 52-week trading range of $51.70 to $80.42. Now shares are down about 12% and trading closer to $59.00 in active trading.
JON C. OGG
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
